Roshan Paudel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roshan Paudel has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Stephanie Ferrante
Michigan Urological Surgery Improvement Collaborative, University of Michigan, Ann Arbor, USA
5 shared publications- Christine Cronin
Dana-Farber Cancer Institute, Boston, MA
3 shared publications Donna L. Berry
Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, USA
3 shared publications- Giulia Ippolito Lane
University of Michigan Ann Arbor Michigan USA
3 shared publications - Michael J. Hassett
Department of Medicine, Harvard Medical School, Boston, MA, United States
3 shared publications - Sandra L. Wong
Dartmouth-Hitchcock Medical Center, Lebanon, NH
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (6) , 990-998
Staff Perspectives on Normalizing and Sustaining Electronic Patient-Reported Outcomes Monitoring at Six US Health Systems
PURPOSE: We assessed the perspectives of staff from six health systems to understand how electronic Symptom Management (eSyM), an eSyM program that supports patients during chemotherapy and after surgery, is normalized and sustained. METHODS: Starting in 2019, we integrated eSyM into routine clinical practice and assessed its effectiveness using a cluster randomized stepped-wedge trial design. At least 1 year after implementation, we administered cross-sectional surveys to elicit the perspectives of physicians, nurses, advanced practice providers (APPs), hospital administrators, information technology, and research staff using the Normalization MeAsure Development (NoMAD) and the Clinical Sustainability Assessment Tool (CSAT). RESULTS: Of the 211 staff who initiated the survey, 169 (80%) completed it. Respondents included 64 nurses (38%), 38 physicians (23%), 20 research staff (12%), 17 APPs (10%), 16 administrators (10%), and nine information technologists (5%). The mean NoMAD familiarity score was 5.90 (standard deviation [SD], 3.06) and the mean score for eSyM becoming a part of routine practice was 4.84 (SD, 3.21), scored on a 0-10 scale. Compared with physicians, nurses reported higher familiarity scores and lower NoMAD domain scores for coherence , cognitive participation , and reflexive monitoring . CSAT scores (scored 1-7) demonstrated moderate sustainability (mean 4.52, SD, 1.61), ranging from a mean of 3.28 (SD, 1.48) among APPs to 5.75 (SD, 0.69) among IT staff. Of the CSAT items, engaged staff and leadership and organizational readiness had the highest (mean 4.89, SD, 1.73) and lowest (mean 4.18, SD, 1.73) scores, respectively ( P < .05). CONCLUSION: Clinical staff reported moderate levels of normalization and capacity for sustainability. Nurses and APPs reported lower levels of sustainability compared with physicians and administrators. Future studies should explore novel workflows and tools that support clinical staff who provide symptom management support.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (6) , 990-998
Open AccessStaff Perspectives on Normalizing and Sustaining Electronic Patient-Reported Outcomes Monitoring at Six US Health Systems
PURPOSE: We assessed the perspectives of staff from six health systems to understand how electronic Symptom Management (eSyM), an eSyM program that supports patients during chemotherapy and after surgery, is normalized and sustained. METHODS: Starting in 2019, we integrated eSyM into routine clinical practice and assessed its effectiveness using a cluster randomized stepped-wedge trial design. At least 1 year after implementation, we administered cross-sectional surveys to elicit the perspectives of physicians, nurses, advanced practice providers (APPs), hospital administrators, information technology, and research staff using the Normalization MeAsure Development (NoMAD) and the Clinical Sustainability Assessment Tool (CSAT). RESULTS: Of the 211 staff who initiated the survey, 169 (80%) completed it. Respondents included 64 nurses (38%), 38 physicians (23%), 20 research staff (12%), 17 APPs (10%), 16 administrators (10%), and nine information technologists (5%). The mean NoMAD familiarity score was 5.90 (standard deviation [SD], 3.06) and the mean score for eSyM becoming a part of routine practice was 4.84 (SD, 3.21), scored on a 0-10 scale. Compared with physicians, nurses reported higher familiarity scores and lower NoMAD domain scores for coherence , cognitive participation , and reflexive monitoring . CSAT scores (scored 1-7) demonstrated moderate sustainability (mean 4.52, SD, 1.61), ranging from a mean of 3.28 (SD, 1.48) among APPs to 5.75 (SD, 0.69) among IT staff. Of the CSAT items, engaged staff and leadership and organizational readiness had the highest (mean 4.89, SD, 1.73) and lowest (mean 4.18, SD, 1.73) scores, respectively ( P < .05). CONCLUSION: Clinical staff reported moderate levels of normalization and capacity for sustainability. Nurses and APPs reported lower levels of sustainability compared with physicians and administrators. Future studies should explore novel workflows and tools that support clinical staff who provide symptom management support.
- Open Access
- 15 April 2026
- Published by MDPI AG in Preprints.org
Bacterial Community Structure and Functional Potential of Fermented Pearl Millet Revealed by 16S rRNA Amplicon Sequencing
Food fermentation is a widely used processing technique that enhances sensory properties, shelf life, and nutritional value, partly through the activity of beneficial microorganisms. This study investigated the microbial communities associated with traditional pearl millet fermentation and their potential nutritional contributions. Pearl millet (TiftLHB open-pollinated variety) was obtained from USDA-ARS and subjected to spontaneous fermentation in sterilized water at 28 ± 2 °C for 72 hours, followed by wet milling and an additional 72-hour fermentation. Microbial DNA was extracted, and 16S rRNA amplicon sequencing was performed after PCR amplification and quality control. Sequence data were analyzed using DADA2 and PICRUSt2 pipelines for taxonomic and functional prediction. The dominant bacterial genera identified were Weissella and Lactobacillus, both commonly associated with cereal fermentations. Weissella is known for reducing antinutrients and contributing to folate production, while the overall microbial profile was consistent with reports from other regions, including the presence of lactic acid bacteria such as Leuconostoc. These findings suggest that spontaneous fermentation of pearl millet supports microbial communities with potential nutritional and functional benefits. Metagenomic approaches may provide an effective strategy for identifying and optimizing beneficial microorganisms to enhance the nutritional quality and health-promoting properties of fermented cereal-based foods.
- 15 April 2026
- Published by MDPI AG in Preprints.org
Open AccessBacterial Community Structure and Functional Potential of Fermented Pearl Millet Revealed by 16S rRNA Amplicon Sequencing
Food fermentation is a widely used processing technique that enhances sensory properties, shelf life, and nutritional value, partly through the activity of beneficial microorganisms. This study investigated the microbial communities associated with traditional pearl millet fermentation and their potential nutritional contributions. Pearl millet (TiftLHB open-pollinated variety) was obtained from USDA-ARS and subjected to spontaneous fermentation in sterilized water at 28 ± 2 °C for 72 hours, followed by wet milling and an additional 72-hour fermentation. Microbial DNA was extracted, and 16S rRNA amplicon sequencing was performed after PCR amplification and quality control. Sequence data were analyzed using DADA2 and PICRUSt2 pipelines for taxonomic and functional prediction. The dominant bacterial genera identified were Weissella and Lactobacillus, both commonly associated with cereal fermentations. Weissella is known for reducing antinutrients and contributing to folate production, while the overall microbial profile was consistent with reports from other regions, including the presence of lactic acid bacteria such as Leuconostoc. These findings suggest that spontaneous fermentation of pearl millet supports microbial communities with potential nutritional and functional benefits. Metagenomic approaches may provide an effective strategy for identifying and optimizing beneficial microorganisms to enhance the nutritional quality and health-promoting properties of fermented cereal-based foods.
- Open Access
- 1 April 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (4) , e264996
Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy
Importance: The longitudinal patterns of patient-reported outcomes and their association with mortality in routine oncology care are largely unexplored. Objectives: To characterize the longitudinal patient-reported outcomes among patients undergoing chemotherapy and evaluate their association with mortality. Design, Setting, and Participants: This secondary analysis assessed patients in the intervention arm of a cluster randomized clinical trial conducted by the Symptom Management Implementation of Patient Reported Outcomes in Oncology (SIMPRO) consortium. Patients with gastrointestinal, gynecologic, or thoracic cancer who started a new chemotherapy regimen and completed at least 1 symptom questionnaire within 180 days at medical oncology clinics at 6 hospitals (Northeast and Southern US) were assessed from September 1, 2019, to August 31, 2023. Data analysis was performed from March to September 2025. Exposure: Electronic health record–integrated symptom questionnaires along with patient education, decision support alerts, and clinical reports to facilitate symptom management. Main Outcomes and Measures: Outcomes were patient-reported symptoms, physical function, overall well-being, and mortality. Multivariable regression identified factors associated with mortality during the 180-day follow-up period with symptoms included as time-varying covariates. Results: Overall, 3735 patients (median [IQR] age, 67 [59-74] years; 2196 [59%] female) submitted 35 059 symptom questionnaires; 1710 (46%) were diagnosed with gastrointestinal, 1163 (31%) with thoracic, and 852 (23%) with gynecologic cancer. On multivariable analysis, moderate (hazard ratio [HR], 2.07; 95% CI, 1.34-3.20; P < .001) and severe (HR, 3.39; 95% CI, 2.20-5.22; P < .001) physical function deficits were associated with a higher hazard of death. Fatigue was the most common symptom reported (29 138 [83%]) followed by pain (19 959 [57%]). The prevalence of severe symptom reports decreased from 1440 of 30 660 reported symptoms (5%) in week 1 to 40 of 3528 reported symptoms (1%) in week 26, whereas moderate symptom reports decreased from 3522 of 30 660 symptoms (11%) to 265 of 3528 (8%). Other time-varying factors associated with higher hazard of death were moderate pain (HR, 1.43; 95%, CI 1.08-1.90; P = .01), severe pain (HR, 1.66; 94% CI, 1.21-2.26; P = .001), moderate dyspnea (HR, 1.31; 95% CI, 1.02-1.69; P = .04), severe dyspnea (HR, 1.62; 95% CI, 1.17-2.24; P = .004), moderate loss in appetite (HR, 1.40; 95% CI, 1.02-1.92; P = .04), and severe loss in appetite (HR, 2.27; 95% CI, 1.55-3.33; P < .001). Conclusions and Relevance: This secondary analysis of a cluster randomized clinical trial of patients with cancer characterized the burden of cancer-related symptoms and described normative experiences for patients receiving chemotherapy for 3 common types of cancer and found that mortality was associated with patients’ evolving health status. These findings may help inform programs to monitor and manage symptoms and to deliver targeted interventions that enhance outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT03850912
- 1 April 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (4) , e264996
Open AccessLongitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy
Importance: The longitudinal patterns of patient-reported outcomes and their association with mortality in routine oncology care are largely unexplored. Objectives: To characterize the longitudinal patient-reported outcomes among patients undergoing chemotherapy and evaluate their association with mortality. Design, Setting, and Participants: This secondary analysis assessed patients in the intervention arm of a cluster randomized clinical trial conducted by the Symptom Management Implementation of Patient Reported Outcomes in Oncology (SIMPRO) consortium. Patients with gastrointestinal, gynecologic, or thoracic cancer who started a new chemotherapy regimen and completed at least 1 symptom questionnaire within 180 days at medical oncology clinics at 6 hospitals (Northeast and Southern US) were assessed from September 1, 2019, to August 31, 2023. Data analysis was performed from March to September 2025. Exposure: Electronic health record–integrated symptom questionnaires along with patient education, decision support alerts, and clinical reports to facilitate symptom management. Main Outcomes and Measures: Outcomes were patient-reported symptoms, physical function, overall well-being, and mortality. Multivariable regression identified factors associated with mortality during the 180-day follow-up period with symptoms included as time-varying covariates. Results: Overall, 3735 patients (median [IQR] age, 67 [59-74] years; 2196 [59%] female) submitted 35 059 symptom questionnaires; 1710 (46%) were diagnosed with gastrointestinal, 1163 (31%) with thoracic, and 852 (23%) with gynecologic cancer. On multivariable analysis, moderate (hazard ratio [HR], 2.07; 95% CI, 1.34-3.20; P < .001) and severe (HR, 3.39; 95% CI, 2.20-5.22; P < .001) physical function deficits were associated with a higher hazard of death. Fatigue was the most common symptom reported (29 138 [83%]) followed by pain (19 959 [57%]). The prevalence of severe symptom reports decreased from 1440 of 30 660 reported symptoms (5%) in week 1 to 40 of 3528 reported symptoms (1%) in week 26, whereas moderate symptom reports decreased from 3522 of 30 660 symptoms (11%) to 265 of 3528 (8%). Other time-varying factors associated with higher hazard of death were moderate pain (HR, 1.43; 95%, CI 1.08-1.90; P = .01), severe pain (HR, 1.66; 94% CI, 1.21-2.26; P = .001), moderate dyspnea (HR, 1.31; 95% CI, 1.02-1.69; P = .04), severe dyspnea (HR, 1.62; 95% CI, 1.17-2.24; P = .004), moderate loss in appetite (HR, 1.40; 95% CI, 1.02-1.92; P = .04), and severe loss in appetite (HR, 2.27; 95% CI, 1.55-3.33; P < .001). Conclusions and Relevance: This secondary analysis of a cluster randomized clinical trial of patients with cancer characterized the burden of cancer-related symptoms and described normative experiences for patients receiving chemotherapy for 3 common types of cancer and found that mortality was associated with patients’ evolving health status. These findings may help inform programs to monitor and manage symptoms and to deliver targeted interventions that enhance outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT03850912
- Open Access
- 7 February 2026
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 21 (1) , 1
Shared Decision Making, Decision Aids and Patient Reported Outcome Measures for Overactive Bladder Care: A Review
Purpose of Review: Shared decision making (SDM) is integral to clinical decision making for OAB. SDM is a collaborative process that takes patients’ values, preferences, and goals into account when deciding on their treatment options. Decision aids (DAs) can support SDM and patient-reported outcomes (PROs) help to assess the outcomes most important to the patient. Recent Findings: Twenty-five articles were retrieved and reviewed. Our search for literature about SDM in OAB found that physician recommendation is a key decisional component for patients yet that physicians’ priorities may differ widely from patients’ preferences. We evaluated currently available decision aids for OAB and found that none of the peer reviewed aids are publicly available, though non-peer reviewed, paper-based decision aids are available online. At least 10 PROs are available for OAB, these are regularly used in trials of efficacy and are increasingly being implemented in clinical practice. Finally, artificial intelligence applications such as large language models and machine learning based clinical risk prediction tools are emerging as a new facet to augment SDM, but there are limitations on the quality and the clinical implementation of these tools. Summary: Decision aids and patient reported outcome measures are integral to the delivery of patient-centered, individualized, shared decision making for OAB. Despite this, few freely available DAs exist and many PROs are available, which makes comparison of outcomes between treatments challenging. Emerging AI technologies may further augment the SDM however require validation prior to clinical use.
- 7 February 2026
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 21 (1) , 1
Open AccessShared Decision Making, Decision Aids and Patient Reported Outcome Measures for Overactive Bladder Care: A Review
Purpose of Review: Shared decision making (SDM) is integral to clinical decision making for OAB. SDM is a collaborative process that takes patients’ values, preferences, and goals into account when deciding on their treatment options. Decision aids (DAs) can support SDM and patient-reported outcomes (PROs) help to assess the outcomes most important to the patient. Recent Findings: Twenty-five articles were retrieved and reviewed. Our search for literature about SDM in OAB found that physician recommendation is a key decisional component for patients yet that physicians’ priorities may differ widely from patients’ preferences. We evaluated currently available decision aids for OAB and found that none of the peer reviewed aids are publicly available, though non-peer reviewed, paper-based decision aids are available online. At least 10 PROs are available for OAB, these are regularly used in trials of efficacy and are increasingly being implemented in clinical practice. Finally, artificial intelligence applications such as large language models and machine learning based clinical risk prediction tools are emerging as a new facet to augment SDM, but there are limitations on the quality and the clinical implementation of these tools. Summary: Decision aids and patient reported outcome measures are integral to the delivery of patient-centered, individualized, shared decision making for OAB. Despite this, few freely available DAs exist and many PROs are available, which makes comparison of outcomes between treatments challenging. Emerging AI technologies may further augment the SDM however require validation prior to clinical use.
- Open Access
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400145
Use of Patient-Reported Outcomes in Risk Prediction Model Development to Support Cancer Care Delivery: A Scoping Review
PURPOSE: The integration of patient-reported outcomes (PROs) into electronic health records (EHRs) has enabled systematic collection of symptom data to manage post-treatment symptoms. The use and integration of PRO data into routine care are associated with overall treatment success, adherence, and satisfaction. Clinical trials have demonstrated the prognostic value of PROs including physical function and global health status in predicting survival. It is unknown to what extent routinely collected PRO data are used in the development of risk prediction models (RPMs) in oncology care. The objective of the scoping review is to assess how PROs are used to train risk RPMs to predict patient outcomes in oncology care. METHODS: Using the scoping review methodology outlined in the Joanna Briggs Institute Manual for Evidence Synthesis, we searched four databases (MEDLINE, CINAHL, Embase, and Web of Science) to locate peer-reviewed oncology articles that used PROs as predictors to train models. Study characteristics including settings, clinical outcomes, and model training, testing, validation, and performance data were extracted for analyses. RESULTS: Of the 1,254 studies identified, 18 met inclusion criteria. Most studies performed retrospective analyses of prospectively collected PRO data to build prediction models. Post-treatment survival was the most common outcome predicted. Discriminative performance of models trained using PROs was better than models trained without PROs. Most studies did not report model calibration. CONCLUSION: Systematic collection of PROs in routine practice provides an opportunity to use patient-reported data to develop RPMs. Model performance improves when PROs are used in combination with other comprehensive data sources.
- 1 November 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400145
Open AccessUse of Patient-Reported Outcomes in Risk Prediction Model Development to Support Cancer Care Delivery: A Scoping Review
PURPOSE: The integration of patient-reported outcomes (PROs) into electronic health records (EHRs) has enabled systematic collection of symptom data to manage post-treatment symptoms. The use and integration of PRO data into routine care are associated with overall treatment success, adherence, and satisfaction. Clinical trials have demonstrated the prognostic value of PROs including physical function and global health status in predicting survival. It is unknown to what extent routinely collected PRO data are used in the development of risk prediction models (RPMs) in oncology care. The objective of the scoping review is to assess how PROs are used to train risk RPMs to predict patient outcomes in oncology care. METHODS: Using the scoping review methodology outlined in the Joanna Briggs Institute Manual for Evidence Synthesis, we searched four databases (MEDLINE, CINAHL, Embase, and Web of Science) to locate peer-reviewed oncology articles that used PROs as predictors to train models. Study characteristics including settings, clinical outcomes, and model training, testing, validation, and performance data were extracted for analyses. RESULTS: Of the 1,254 studies identified, 18 met inclusion criteria. Most studies performed retrospective analyses of prospectively collected PRO data to build prediction models. Post-treatment survival was the most common outcome predicted. Discriminative performance of models trained using PROs was better than models trained without PROs. Most studies did not report model calibration. CONCLUSION: Systematic collection of PROs in routine practice provides an opportunity to use patient-reported data to develop RPMs. Model performance improves when PROs are used in combination with other comprehensive data sources.
- Open Access
- 5 March 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (7) , 1137-1144
Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial
Optimal methods for deploying electronic patient-reported outcomes to manage symptoms in routine oncologic practice remain uncertain. The electronic symptom management (eSyM) program asks chemotherapy and surgery patients to self-report 12 common symptoms regularly. Feedback from nurses and patients led to changing the recall period from the past 7 days to the past 24 hours. Using questionnaires submitted during the 16 weeks surrounding the recall period change, we assessed the likelihood of reporting severe or moderate and severe symptoms across 12 common symptoms and separately for the 5 most prevalent symptoms. Interrupted time-series analyses modeled the effects of the change using generalized linear mixed-effects models. Surgery and chemotherapy cohorts were analyzed separately. Study-wide effects were estimated using a meta-analysis method. In total, 1692 patients from 6 institutions submitted 7823 eSyM assessments during the 16 weeks surrounding the recall period change. Shortening the recall period was associated with lower odds of severe symptom reporting in the surgery cohort (odds ratio = 0.65, 95% confidence interval = 0.46 to 0.93; P = .02) and lower odds of moderate and severe symptom reporting in the chemotherapy cohort (odds ratio = 0.83, 95% confidence interval = 0.71 to 0.97; P = .02). Among the most prevalent symptoms, 24-hour recall was associated with a lower rate of reporting postoperative constipation but no differences in reporting rates for other symptoms. A shorter recall period was associated with a reduction in the proportion of patients reporting moderate-severe symptoms. The optimal recall period may vary depending on whether electronic patient-reported outcomes are collected for active symptom management, as a clinical trial endpoint, or another purpose. ClinicalTrials.gov ID NCT03850912.
- 5 March 2024
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (7) , 1137-1144
Open AccessEffects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial
Optimal methods for deploying electronic patient-reported outcomes to manage symptoms in routine oncologic practice remain uncertain. The electronic symptom management (eSyM) program asks chemotherapy and surgery patients to self-report 12 common symptoms regularly. Feedback from nurses and patients led to changing the recall period from the past 7 days to the past 24 hours. Using questionnaires submitted during the 16 weeks surrounding the recall period change, we assessed the likelihood of reporting severe or moderate and severe symptoms across 12 common symptoms and separately for the 5 most prevalent symptoms. Interrupted time-series analyses modeled the effects of the change using generalized linear mixed-effects models. Surgery and chemotherapy cohorts were analyzed separately. Study-wide effects were estimated using a meta-analysis method. In total, 1692 patients from 6 institutions submitted 7823 eSyM assessments during the 16 weeks surrounding the recall period change. Shortening the recall period was associated with lower odds of severe symptom reporting in the surgery cohort (odds ratio = 0.65, 95% confidence interval = 0.46 to 0.93; P = .02) and lower odds of moderate and severe symptom reporting in the chemotherapy cohort (odds ratio = 0.83, 95% confidence interval = 0.71 to 0.97; P = .02). Among the most prevalent symptoms, 24-hour recall was associated with a lower rate of reporting postoperative constipation but no differences in reporting rates for other symptoms. A shorter recall period was associated with a reduction in the proportion of patients reporting moderate-severe symptoms. The optimal recall period may vary depending on whether electronic patient-reported outcomes are collected for active symptom management, as a clinical trial endpoint, or another purpose. ClinicalTrials.gov ID NCT03850912.
- 1 January 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (1) , 77-84
Assessing Patient Readiness for an Electronic Patient-Reported Outcome–Based Symptom Management Intervention in a Multisite Study
PURPOSE: While the use of electronic patient-reported outcomes (ePROs) in routine clinical practice is increasing, barriers to patient engagement limit adoption. Studies have focused on technology access as a key barrier, yet other characteristics may also confound readiness to use ePROs including patients' confidence in using technology and confidence in asking clinicians questions. METHODS: To assess readiness to use ePROs, adult patients from six US-based health systems who started a new oncology treatment or underwent a cancer-directed surgery were invited to complete a survey that assessed access to and confidence in the use of technology, ease of asking clinicians questions about health, and symptom management self-efficacy. Multivariable ordinal logistic regression models were fit to assess the association between technology confidence, ease of asking questions, and symptom management self-efficacy. RESULTS: We contacted 3,212 individuals, and 1,043 (33%) responded. The median age was 63 years, 68% were female, and 75% reported having access to patient portals. Over 80% had two or more electronic devices. Most patients reported high technology confidence, higher ease of asking clinicians questions, and high symptom management self-efficacy (n = 692; 66%). Patients with high technology confidence also reported higher ease of asking nurses about their health (adjusted odds ratio [AOR], 4.58 [95% CI, 2.36 to 8.87]; P ≤ .001). Those who reported higher ease of asking nurses questions were more likely to report higher confidence in managing symptoms (AOR, 30.54 [95% CI, 12.91 to 72.30]; P ≤ .001). CONCLUSION: Patient readiness to use ePROs likely depends on multiple factors, including technology and communication confidence, and symptom management self-efficacy. Future studies should assess interventions to address these factors.
- 1 January 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (1) , 77-84
Assessing Patient Readiness for an Electronic Patient-Reported Outcome–Based Symptom Management Intervention in a Multisite Study
PURPOSE: While the use of electronic patient-reported outcomes (ePROs) in routine clinical practice is increasing, barriers to patient engagement limit adoption. Studies have focused on technology access as a key barrier, yet other characteristics may also confound readiness to use ePROs including patients' confidence in using technology and confidence in asking clinicians questions. METHODS: To assess readiness to use ePROs, adult patients from six US-based health systems who started a new oncology treatment or underwent a cancer-directed surgery were invited to complete a survey that assessed access to and confidence in the use of technology, ease of asking clinicians questions about health, and symptom management self-efficacy. Multivariable ordinal logistic regression models were fit to assess the association between technology confidence, ease of asking questions, and symptom management self-efficacy. RESULTS: We contacted 3,212 individuals, and 1,043 (33%) responded. The median age was 63 years, 68% were female, and 75% reported having access to patient portals. Over 80% had two or more electronic devices. Most patients reported high technology confidence, higher ease of asking clinicians questions, and high symptom management self-efficacy (n = 692; 66%). Patients with high technology confidence also reported higher ease of asking nurses about their health (adjusted odds ratio [AOR], 4.58 [95% CI, 2.36 to 8.87]; P ≤ .001). Those who reported higher ease of asking nurses questions were more likely to report higher confidence in managing symptoms (AOR, 30.54 [95% CI, 12.91 to 72.30]; P ≤ .001). CONCLUSION: Patient readiness to use ePROs likely depends on multiple factors, including technology and communication confidence, and symptom management self-efficacy. Future studies should assess interventions to address these factors.
- Open Access
- 20 March 2023
- Published by Springer Nature in Implementation Science Communications
- Vol. 4 (1) , 1
Correction: Implementation of prostate cancer treatment decision aid in Michigan: a qualitative study
- 20 March 2023
- Published by Springer Nature in Implementation Science Communications
- Vol. 4 (1) , 1
Open AccessCorrection: Implementation of prostate cancer treatment decision aid in Michigan: a qualitative study
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 209 (1) , 178-179
Reply by Authors
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 209 (1) , 178-179
Reply by Authors
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 209 (1) , 170-179
The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience
Purpose:NCCN favorable intermediate risk prostate cancer (FIRPC) is a heterogeneous disease with varied oncologic and survival outcomes. We describe the Michigan Urological Surgery Improve...
- 1 January 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 209 (1) , 170-179
The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience
Purpose:NCCN favorable intermediate risk prostate cancer (FIRPC) is a heterogeneous disease with varied oncologic and survival outcomes. We describe the Michigan Urological Surgery Improve...